Patents by Inventor Eva Leander

Eva Leander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process
    Patent number: 6747155
    Abstract: The present invention relates to a novel process for the preparation of the magnesium salt of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole trihydrate, i.e. S-omeprazole magnesium salt trihydrate. The present invention also relates to the S-omeprazole magnesium salt trihydrate prepared in accordance with the new process and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: June 8, 2004
    Assignee: AstraZeneca AB
    Inventors: Anders Kronström, Eva Leander, Anders Mattson, Karin Jansson, Martin Bohlin
  • Potassium salt of S-omeprazole
    Patent number: 6677455
    Abstract: The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: January 13, 2004
    Assignee: AstraZeneca AB
    Inventors: Anders Kronström, Eva Leander, Anders Mattson
  • Process
    Publication number: 20030004190
    Abstract: The present invention relates to a novel process for the preparation of the magnesium salt of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole trihydrate, ie. S-omeprazole magnesium salt trihydrate. The present invention also relates to the S-omeprazole magnesium salt trihydrate prepared in accordance with the new process and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
    Type: Application
    Filed: April 1, 2002
    Publication date: January 2, 2003
    Inventors: Anders Kronstrom, Eva Leander, Anders Mattson, Karin Jansson, Martin Bohlin
  • Potassium salt of S-omeprazole
    Publication number: 20020198239
    Abstract: The present invention relates to a novel form of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
    Type: Application
    Filed: February 14, 2002
    Publication date: December 26, 2002
    Inventors: Anders Kronstrom, Eva Leander, Anders Mattson